Who is sponsoring ChallengeIII?

ChallengeIII is sponsored by Socrates Herrera Valencia.

What drugs are being tested in ChallengeIII?

Interventions: P. vivax infected mosquito bites.

What is the status of ChallengeIII?

ChallengeIII is currently COMPLETED.

Last reviewed 2014-01-13 · How we verify

Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites. (ChallengeIII)

NCT01585077 Phase 1/Phase 2 COMPLETED

This study is a randomized clinical trial designed to compare the susceptibility of naive and pre-immune volunteers to infectious challenge with viable Plasmodium vivax sporozoites. The term preimmune hereafter denoted only previous experience with infection by this parasite and not a definite state of immunity to malaria infection. The study hypothesis is that pre-immune volunteers present a delayed onset of malaria clinical and parasitological manifestations when compared to naive individuals. The development of this study will establish a protocol for evaluating the effectiveness of vaccine candidates against P. vivax in subsequent Phases IIa and IIb clinical trials.

Details

Lead sponsor	Socrates Herrera Valencia
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	16
Start date	2012-10
Completion	2013-11

Conditions

Malaria

Interventions

P. vivax infected mosquito bites

Primary outcomes

Pre-patent period onset — Two months after the challenge
begining at day 7 after mosquito bites exposure, both groups of volunteers will be evaluated with dayly Thick blood smear to compare the malaria onset between the pre-immune and naive groups.

Countries

Colombia